Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. A pilot study

Hormone and Metabolic Research

Volumn 35, Issue 6, 2003, Pages 382-386

  Boehm, Bernhard O ^a,c   Lang, G ^a   Feldmann, B ^a   Kurkhaus, A ^a   Rosinger, S ^a   Volpert, O ^b   Lang, G K ^a   Bouck, N ^b  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Angiogenesis; Angiogenic Inhibitors; Aqueous Humor; Diabetic Retinopathy; Pigment Epithelium Derived Factor (PEDF); Vascular Endothelial Growth Factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CAPILLARY ENDOTHELIUM; CATARACT EXTRACTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPOPROTEINEMIA; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SAMPLING; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AQUEOUS HUMOR; DIABETIC RETINOPATHY; EYE; EYE PROTEINS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE GROWTH FACTORS; PROTEINS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0042838296     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41362     Document Type: Article

References (32)

1. Klein R. The epidemiology of eye disease. In: Pickup JC, Williams G (eds). Textbook of Diabetes, 2nd edition Oxford: Blackwell Sciences, 1997: 44.1-44.9
2. The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
3. The Diabetes Control and Complications Trial Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
5. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112: 1217-1228
6. Bouck N, Stellmach V, Hsu S. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-174
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364
8. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002; 8: 330-334
9. Feldmann B, Jehle PM, Mohan S, Lang GE, Lang GK, Brueckel J, Boehm BO. Diabetic retinopathy is associated with decreased serum levels of free IGF-1 and changes of IGF-binding proteins. Growth Horm and IGF Res 2000; 10: 53-60
10. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J Clin Invest 2002; 109: 805-815
11. Adamis AP, Miller JW, Bdernal M-T, D'Amico DJ, Folkman J, Yeo T-K, Yeo K-T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450
12. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
13. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461
14. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248
15. Brausewetter F, Jehle PM, Jung MF, Boehm BO, Brueckel J, Hombach V, Osterhues HH. Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-1) and vascular endothelial growth factor (VEGF). Horm Metab Res 2001; 33: 713-720
16. Miller AD, Robinson GS, Smith LEH, Becerra SP. Regulation of pigment epithelium-derived factor (PEDF) production by oxygen. Invest Ophthalmol Vis Sci 2000; 41 (Suppl): S869-S874
17. Gao G, Li Y, Zhang D, Gee S, Crosson G, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001; 489: 270-276
18. Okamoto T, Oikawa S, Toyota T. Absence of angiogenesis-inhibitory activity in aqueous humor of diabetic rabbits. Diabetes 1990; 39: 12-16
19. Tapper D, Langer R, Bellows AR, Folkman J. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery 1979; 86: 36-40
20. Ortego J, Escribano J, Beccera SP, Coca-Prados M. Gene expression of the neurotrophic pigment epithelium-derived factor in the human ciliary epithelium: synthesis and secretion into the aqueous humor. Invest Ophthalmol Vis Sci 1996; 37: 2759-2767
21. Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43: 1168-1175
22. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia induced retinopathy by the natural ocular anti-angiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98: 2593-2597
23. Chader GJ. PEDF: raising both hopes and questions in controlling angiogenesis. Proc Natl Acad Sci USA 2001; 98: 2122-2124
24. Becerra SP. Structure-function studies on PEDF a noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 1997; 425: 223-237
25. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428-2434
26. Cayouette M, Smith SB, Becerra SP, Gravel C. Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 1999; 6: 523-532
27. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 1999; 58: 719-728
28. Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinns JF. In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Investigative Ophthalmol Vis Sci 2001; 42: 1646-1652
29. Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota S-I, Mochizuki M. Novel mechanisms for age-related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323-333
30. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002; 134: 220-227
31. Spranger J, Osterhoff M, Reimann M, Möhlig M, Ristow M, Francis MF, Cristofalo V, Hames H-P, Smith G, Boulton M, Pfeiffer AFH. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001; 50: 2641-2645
32. Boehm BO, Lang GK, Jehle PM, Feldmann B*, Lang GE*. Octreotide reduces risk for vitreous hemorrhages and loss of visual acuity in patients with high risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33: 300-306 (* contributed equally)